These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 25608772)

  • 41. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
    Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact on survival of nuclear atypia in epithelioid malignant mesothelioma.
    Mlika M; Limam M; Benzarti A; Mezni F
    Adv Respir Med; 2019; 87(2):90-95. PubMed ID: 31038719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
    Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
    Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
    Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
    Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
    Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
    Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
    Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of CD10 Immunohistochemical Expression in Predicting Aggressive Behavior of Phylloides Tumors.
    Tariq MU; Haroon S; Kayani N
    Asian Pac J Cancer Prev; 2015; 16(8):3147-52. PubMed ID: 25921112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initial analysis of the international association for the study of lung cancer mesothelioma database.
    Rusch VW; Giroux D; Kennedy C; Ruffini E; Cangir AK; Rice D; Pass H; Asamura H; Waller D; Edwards J; Weder W; Hoffmann H; van Meerbeeck JP;
    J Thorac Oncol; 2012 Nov; 7(11):1631-9. PubMed ID: 23070243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
    PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. c-Met expression and MET amplification in malignant pleural mesothelioma.
    Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
    Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.
    Hysi I; Le Pimpec-Barthes F; Alifano M; Venissac N; Mouroux J; Regnard JF; Riquet M; Porte H
    Oncol Rep; 2014 Jan; 31(1):415-21. PubMed ID: 24142233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
    J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
    Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
    Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.
    Shia J; Qin J; Erlandson RA; King R; Illei P; Nobrega J; Yao D; Klimstra DS
    Virchows Arch; 2005 Nov; 447(5):828-34. PubMed ID: 16021506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reproducibility of histological subtyping of malignant pleural mesothelioma.
    Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
    Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.